Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroyoshi Nishikawa

Showing results (161-170 of 197) with videos related to

Pageof 20
Sort By:
Nature|July 12, 2013
Treg induction by a rationally selected mixture of Clostridia strains from the human microbiotaKoji Atarashi, Takeshi Tanoue, Kenshiro Oshima, et al.
Science Translational Medicine|May 13, 2021
CD4<sup>+</sup> T cells are essential for the development of destructive thyroiditis induced by anti-PD-1 antibody in thyroglobulin-immunized miceYoshinori Yasuda, Shintaro Iwama, Daisuke Sugiyama, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 11, 2014
Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigenHisashi Wada, Midori Isobe, Kazuhiro Kakimi, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 28, 2012
Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancerShinichi Fujiwara, Hisashi Wada, Hiroshi Miyata, et al.
Scientific Reports|January 12, 2021
Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimensYukie Kashima, Yosuke Togashi, Shota Fukuoka, et al.
International Journal of Cancer|March 18, 2011
Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccinationJunji Kawada, Hisashi Wada, Midori Isobe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 9, 2022
Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical TrialsHiroki Yukami, Akihito Kawazoe, Yi-Tzu Lin, et al.
Cancer Immunology Research|February 4, 2026
Concurrent Pituitary and Thyroid Immune-Related Adverse Events after Immune Checkpoint Inhibitors Associated with HLA-DR15-related HaplotypesTomoko Kobayashi, Shintaro Iwama, Eri Sugiyama, et al.
Molecular Cancer|September 13, 2024
Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomicsSophie Cousin, Jean-Philippe Guégan, Kohei Shitara, et al.
British Journal of Cancer|June 4, 2024
Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancerYuichiro Tsukada, Hideaki Bando, Koji Inamori, et al.
Pageof 20

Showing results (161-170 of 197) with videos related to

Sort By:
Pageof 20
Nature|July 12, 2013
Treg induction by a rationally selected mixture of Clostridia strains from the human microbiotaKoji Atarashi, Takeshi Tanoue, Kenshiro Oshima, et al.
Science Translational Medicine|May 13, 2021
CD4<sup>+</sup> T cells are essential for the development of destructive thyroiditis induced by anti-PD-1 antibody in thyroglobulin-immunized miceYoshinori Yasuda, Shintaro Iwama, Daisuke Sugiyama, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 11, 2014
Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigenHisashi Wada, Midori Isobe, Kazuhiro Kakimi, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 28, 2012
Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancerShinichi Fujiwara, Hisashi Wada, Hiroshi Miyata, et al.
Scientific Reports|January 12, 2021
Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimensYukie Kashima, Yosuke Togashi, Shota Fukuoka, et al.
International Journal of Cancer|March 18, 2011
Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccinationJunji Kawada, Hisashi Wada, Midori Isobe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 9, 2022
Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical TrialsHiroki Yukami, Akihito Kawazoe, Yi-Tzu Lin, et al.
Cancer Immunology Research|February 4, 2026
Concurrent Pituitary and Thyroid Immune-Related Adverse Events after Immune Checkpoint Inhibitors Associated with HLA-DR15-related HaplotypesTomoko Kobayashi, Shintaro Iwama, Eri Sugiyama, et al.
Molecular Cancer|September 13, 2024
Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomicsSophie Cousin, Jean-Philippe Guégan, Kohei Shitara, et al.
British Journal of Cancer|June 4, 2024
Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancerYuichiro Tsukada, Hideaki Bando, Koji Inamori, et al.
Pageof 20